{
    "clinical_study": {
        "@rank": "121204", 
        "arm_group": [
            {
                "arm_group_label": "H5N2 primed", 
                "arm_group_type": "Experimental", 
                "description": "volunteers who previously received two intranasal doses of the live attenuated influenza vaccine (LAIV) in protocol LAIV H5N2-01"
            }, 
            {
                "arm_group_label": "Volunteers who are LAIV H5N2 naive", 
                "arm_group_type": "Active Comparator", 
                "description": "na\u00efve subjects who either received intranasal placebo in LAIV H5N2-01 or are newly recruited to this study"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can\n      induce a  long-lasting immune memory by comparing the immunologic response to two doses of\n      the OrniFlu\u00ae inactivated vaccine given to subjects previously primed with LAIV and subjects\n      who did not received LAIV."
        }, 
        "brief_title": "Immunogenicity of H5N1 Vaccine Following H5N2", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza Prevention", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "This is a an open-label study to evaluate immunogenic activity of the OrniFlu\u00ae  inactivated\n      influenza vaccine which will be given to healthy adult volunteers who participated in a\n      double blind placebo-controlled study in protocol LAIV H5N2-01 at the Institute of Influenza\n      in September-October 2012."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Legal male or female adult 18 through 51 years of age at the enrollment visit\n\n          -  Literate and willing to provide written informed consent\n\n          -  A signed informed consent\n\n          -  Free of obvious health problems, as established by the medical history and screening\n             evaluations, including physical examination\n\n          -  Capable and willing to complete a memory aid and willing to return for all follow-up\n             visits\n\n          -  For females, willing to take reliable birth control measures through Day 56\n\n        Exclusion Criteria:\n\n          -  Participation in another clinical trial involving any investigational agent within\n             the previous three months or planned enrollment in such a trial during the period of\n             this study\n\n          -  Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to\n             postpone receipt\n\n          -  Participation in any other clinical trials involving any H5-matched influenza\n             vaccines except that in Protocol LAIV-H5N2-01\n\n          -  Current or recent (within two weeks of enrollment) acute respiratory illness with or\n             without fever\n\n          -  Other acute illness at the time of study enrollment\n\n          -  Receipt of immunoglobulin or other blood products within three months prior to study\n             enrollment or planned receipt during study period\n\n          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of\n             immunosuppressants and/or immune-modulating therapy within six months prior to study\n             enrollment\n\n          -  History of bronchial asthma\n\n          -  Hypersensitivity after previous administration of any (not only influenza) vaccines.\n\n          -  Other AE following immunization at least possibly related to previous receipt of any\n             (not only influenza) vaccine\n\n          -  Suspected or known hypersensitivity to any of the study vaccine components, including\n             protein of chicken eggs\n\n          -  Seasonal (autumnal) hypersensitivity to the natural environment\n\n          -  Acute or chronic clinically significant abnormality, as determined by medical\n             history, physical examination or clinical laboratory screening tests, which in the\n             opinion of the investigator, might interfere with the study objectives. Subjects with\n             physical examination findings or clinical laboratory screening results which would be\n             graded 2 or higher on the AE severity grading scale  will be excluded from entry into\n             the study\n\n          -  History of leukemia or any other blood diseases or solid organ cancer\n\n          -  History of thrombocytopenic purpura or known bleeding disorder\n\n          -  History of seizures\n\n          -  Known or suspected immunosuppressive or immunodeficient condition of any kind,\n             including HIV infection\n\n          -  Known chronic HBV or HCV infection\n\n          -  Known tuberculosis infection or evidence of previous tuberculosis exposure\n\n          -  History of chronic alcohol abuse and/or illegal drug use\n\n          -  Pregnancy or lactation.\n\n               -  Systemic connective tissue disorders\n\n          -  Adrenal gland diseases\n\n          -  Hereditary, degenerative and progredient diseases of the nervous system\n\n          -  Any condition that, in the opinion of the investigator, would increase the health\n             risk to the subject if he/she participates in the study or would interfere with the\n             evaluation of the study objectives\n\n          -  Allergic, including anaphylactic, reactions to any (not only influenza) vaccines"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "51 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153671", 
            "org_study_id": "LAIV-H5N2-02"
        }, 
        "intervention": {
            "arm_group_label": [
                "H5N2 primed", 
                "Volunteers who are LAIV H5N2 naive"
            ], 
            "intervention_name": "Orniflu inactivated influenza vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "LAIV H5N2", 
            "Influenza vaccine", 
            "Russia"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Petersburg", 
                    "country": "Russian Federation"
                }, 
                "name": "Research Institute of Influenza"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity of OrniFlu\u00ae Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects", 
        "overall_official": {
            "affiliation": "Research Institute of Influenza", 
            "last_name": "Oleg I Kiselev, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Proportion of subjects exhibiting seroresponses in  selected assays (HAI, microneutralization and ELISA) in the prime-boost and the control groups.\n]", 
                "measure": "immunologic response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks following vaccination"
            }, 
            {
                "description": "Antibody GMTs in each group of study subjects for assays employed.", 
                "measure": "immunologic response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153671"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Post-vaccination local and systemic reactogenicity and adverse events to the OrniFlu\u00ae inactivated influenza vaccine in subjects previously primed with LAIV H5N2 and in na\u00efve subjects.", 
            "measure": "safety", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks after each vaccination"
        }, 
        "source": "PATH", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Federal State Unitary Company \"Microgen Scientific Industrial Company for Immunobiological Medicines\" of the Ministry of Health of the Russian Federation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institute of Experimental Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Russian Institute of Influenza", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "PATH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}